Argenx stock holds near recent highs as Jefferies sticks to Buy rating
Published on 09/17/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx stock (ISIN NL0010832176) ended the Nasdaq session on September 15, 2026 at USD 1,001.50, a marginal decline of 0.02% versus the prior close according to a recent overview from ad hoc news, leaving the shares comfortably within their latest trading range and below key analyst targets.ad hoc news According to the same note dated September 16, 2026, Jefferies reiterated its Buy rating on Argenx and maintained a USD 1,215 price target, keeping a clear valuation buffer in place for investors.
Jefferies reiteration keeps upside buffer
As ad hoc news reports in its September 16, 2026 market update, Jefferies confirmed a Buy rating on Argenx stock and left its price target unchanged at USD 1,215, underscoring continued confidence in the company’s growth outlook.ad hoc news With the Nasdaq close at USD 1,001.50 on September 15, 2026, the shares traded roughly one sixth below that analyst target, illustrating that the market still prices in a substantial potential upside if the firm delivers on its pipeline and commercial plans.ad hoc news
According to MarketBeat, Argenx stock carried a consensus rating of Moderate Buy as of mid-September 2026, with an average target price of USD 1,158.61 across covered analysts, positioning the Jefferies USD 1,215 view slightly above the broader consensus.MarketBeat The same MarketBeat overview notes that the stock opened at USD 984.69 on September 17, 2026, after recent gains pushed it close to the upper end of its 52-week trading corridor.MarketBeat
Price level and trading range
Per MarketBeat data, Argenx stock’s 52-week low stood at USD 661.85 while the 52-week high reached USD 1,072.75, highlighting a wide performance span for shareholders over the past year.MarketBeat Against this backdrop, the opening price of USD 984.69 on September 17, 2026 places the shares closer to their 52-week high than their low, a positioning that indicates that much of the recent rally is intact even after minor pullbacks.MarketBeat
Data from a Nasdaq-linked quote page cited by Yahoo Finance show that Argenx shares closed at USD 984.69 on Nasdaq on September 16, 2026, marking a 0.50% daily gain and confirming that the stock has been trading in a relatively narrow band around the USD 1,000 mark in recent sessions.Yahoo Finance The same quote snapshot shows a pre-market indication of USD 986.52 on September 17, 2026, suggesting a mildly positive bias as U.S. trading gets underway.Yahoo Finance
Fundamental backdrop and upcoming data
According to the Baron Health Care Fund’s second-quarter 2026 shareholder letter, Argenx delivered robust first-quarter results, with revenue rising 84% year over year and an operating margin of 22%, underscoring the scalability of its autoimmune-focused portfolio.Seeking Alpha In the same letter dated mid-September 2026, the fund notes that Argenx shares rose in the second quarter following those first-quarter results and a meaningful expansion of commercial insurance coverage for its UNITY test and the new UNITY Confirm product, which can replace more invasive procedures to confirm genetic diagnoses after a high-risk UNITY screening result.Seeking Alpha
The Baron Health Care Fund commentary also points out that investors are watching several clinical readouts expected later in 2026, including data from studies of Argenx’s leading FcRn inhibitor Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, with results anticipated in the third quarter of 2026, as well as results from empasibrupart in multifocal motor neuropathy in the fourth quarter of 2026.Seeking Alpha For shareholders, these upcoming data points represent both an opportunity and a clear risk factor: positive efficacy and safety results could justify the valuation premium implied by analyst targets, while disappointing outcomes would likely weigh on the share price given the importance of Vyvgart and related assets to Argenx’s long-term growth story.Seeking Alpha
Stock near USD 1,000 mark on Nasdaq
With Argenx stock opening at USD 984.69 on Nasdaq on September 17, 2026, based on MarketBeat data, the shares remain close to the psychologically important USD 1,000 level and within roughly 8% of their 52-week high of USD 1,072.75, while still trading more than 48% above the 52-week low of USD 661.85.MarketBeat For investors, the combination of a strong first-quarter revenue and margin profile, an active clinical pipeline with near-term readouts and an unchanged Buy rating from Jefferies at USD 1,215 creates a setup in which fundamental progress and trial outcomes will likely determine whether the stock can move closer to the analyst targets or consolidate around current levels.
Argenx stock key data
- Company: Argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Trading venue: Nasdaq
- Price (as of September 17, 2026): 984.69 USD
- Market capitalization: 60.92 billion USD (as of September 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: Nasdaq-listed biotech
